
Home » Covance Revenues Up, Maintains Guidance
Covance Revenues Up, Maintains Guidance
January 29, 2009
Covance released strong fourth quarter and year end 2008 financial results late Wednesday with revenue increases in both early and late-stage development segments.
Total fourth quarter net revenues were $439 million, up 6.7% from the same period last year. Net income for the quarter was $45.6 million, down 2.5% year over year, with diluted earnings per share of $0.72, down 0.6% from the same quarter last year.
Net revenues for early development were $214.2 million, up 3.1% from $207.9 million in the fourth quarter of 2007. Late-stage development revenues were $224.4 million, up 10.5% from $203.1 million in the same period last year.
While both early- and late-stage development revenues were up, profitability for the early-stage segment declined to 21.4% from 24.8% for the fourth quarter last year.
"Reduced demand in our Early Development segment from a combination of a lower level of new project initiations and increased project delays in our toxicology and clinical pharmacology services led to a sequential decline in segment revenue and operating income," said Covance chairman and CEO Joe Herring in a company release.
Covance’s late-stage development segment increased its operating margin from 16% in Q4 2007 to 19.6% in the fourth quarter of 2008.
Because of the strength in its late-stage development segment, Covance maintained its 2009 full-year revenue growth guidance of 5% to 10% year over year and earnings per share in the range of $3 to $3.20.
In afternoon trading, Covance’s share prices were up almost 8% to $39.72.
Upcoming Events
-
25Apr
-
26Apr
-
27Apr
-
17May
-
21May